AstraZeneca halted a Phase 3 lung cancer trial of volrustomig after an interim data review indicated survival endpoints were unlikely to be met compared with an active comparator. The decision represents a pipeline setback that adds to recent Phase 3 failures and ongoing portfolio reassessment. Volrustomig is part of AstraZeneca’s effort to build late-stage oncology momentum around bispecific concepts and combination strategies. In this instance, the company moved to stop the study following an Independent Data Monitoring Committee recommendation. The halt raises questions about how quickly AstraZeneca can reallocate resources to other lung cancer programs and how it will manage investor expectations amid multiple oncology and cardiovascular readouts in close succession. For biotech teams, it also underscores how interim checks can rapidly narrow clinical pathways when survival targets are not supported early.